Medical Abortion Self-Confirmation (MASC)

Medical Abortion Clinical Trial

— MASC  

Official title:

Medication Abortion Self-Confirmation (MASC): Comparison of Two Home Pregnancy Tests as an Alternative to Office Follow-up

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03148587
• Other study ID #: 39816
• Status: Completed
• Phase: N/A
• Start date: May 1, 2017
• Est. completion date: May 31, 2018

Study information

• Verified date: June 2019
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to investigate the ability of participants to perform and accurately interpret the multi-level pregnancy test and the low sensitivity pregnancy test following medication abortion, without routine provider contact.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 88
• Est. completion date: May 31, 2018
• Est. primary completion date: May 31, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Gestational age of less than or equal to 63 days

• English speaking

• Determined by the site investigator or designee to be fully eligible for medical abortion with mifepristone followed by misoprostol according to the site's standard criteria

• In the judgement of the site investigator, she is capable of giving informed consent and she has signed the study informed consent or assent form

Exclusion Criteria:

• Allergy to mifepristone and/or misoprostol

• Non-english speaking

• Inability to access internet

Related Conditions & MeSH terms

• Medical Abortion

Intervention

Behavioral:
• Self-assessment: MLPT
Patients enrolled in the study will self-assess the outcomes of their medical abortion using the multi-level pregnancy test.
• Self-assessment: LSPT
Patients enrolled in the study will self-assess the outcomes of their medical abortion using the low sensitivity pregnancy test.

Locations

Country	Name	City	State
United States	Stanford Health Care	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correct interpretation of pregnancy test		4 weeks after taking medication abortion medication, mifepristone